IRES-Driven Axonal Protein Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective solutions for promoting axonal regeneration and growth after injury, particularly in conditions such as spinal cord injury, diabetic neuropathy, and other axonopathies, where axonal injury leads to paralysis and loss of innervation.
Innovation Solution
The use of recombinant nucleic acids and RNA viruses that express specific polypeptides in mammalian axons, utilizing internal ribosome entry sites (IRES) linked to viral genomes, to deliver coding sequences for proteins that modulate axonal growth or function, such as kinases, transcription factors, and neurotrophic factors, directly into axons for expression and treatment of injured axons.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to deliver therapeutic proteins to axons, then the treatment approach is simple, but the delivery efficiency and specificity to axonal compartments is insufficient
Solution Approach 1:
The patent divides the protein delivery system into axon-specific and cell body-specific components using separate viral vectors. The axonal delivery vector contains an IRES-driven expression system that specifically targets axonal compartments, while the cell body vector uses a cap-dependent translation system. This segmentation allows independent optimization of delivery efficiency for each compartment without cross-interference.
Solution Approach 2:
The patent introduces IRES (internal ribosome entry site) elements as molecular intermediaries that enable cap-independent translation specifically in axonal compartments. This intermediary mechanism allows the therapeutic protein to be translated from the delivered mRNA without requiring nuclear import or cytoplasmic mixing, thereby achieving compartment-specific expression with high reliability.
2Reliability
If proteins are expressed in axons using viral transduction, then axonal regeneration is promoted, but the risk of viral integration and off-target effects increases
Solution Approach 1:
The patent extracts the translation initiation mechanism from the nuclear control system and places it directly in the axonal cytoplasm through IRES elements. This extraction eliminates the need for viral genome integration into nuclear DNA, as the IRES-driven translation occurs directly from cytoplasmic mRNA in the axon, thereby removing the risk of genotoxic effects while maintaining therapeutic protein expression.
Solution Approach 2:
The patent implements local quality control by restricting viral genome integration to non-dividing neuronal cell bodies while enabling protein expression in post-mitotic axonal compartments. The IRES system ensures that translation occurs only in the axonal compartment where it is needed, preventing off-target effects in the cell body and eliminating concerns about viral integration in dividing cells.
3Adaptability or versatility
If traditional gene delivery methods are used, then the system is easier to construct, but the ability to achieve compartment-specific protein expression in neurons is limited
Solution Approach 1:
The patent introduces dynamic control of protein expression by using the differential translation mechanisms (cap-dependent in cell bodies vs. IRES-mediated in axons) that respond to local cellular conditions. This dynamic system automatically directs protein synthesis to the appropriate compartment based on the local translation machinery availability, achieving compartment-specific expression without complex regulatory elements.
Solution Approach 2:
The patent adds a spatial dimension to gene expression control by utilizing the physical separation of translation initiation mechanisms between cell body and axon compartments. The IRES element operates in a different translational dimension (cap-independent) compared to conventional viral vectors (cap-dependent), enabling spatially-resolved protein expression that targets specific neuronal compartments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the direct expression of proteins within axons that promote axonal regeneration and growth, potentially treating conditions associated with aberrant axon function and injury by facilitating the delivery of therapeutic polypeptides directly to the site of injury, enhancing axonal repair and function.
Implementation Method 1
a protein coding sequence operably linked to an internal ribosome entry site (IRES) in an RNA viral genome can be expressed in a mammalian axon when the RNA genome is transduced into the axon
Data Source
AI summary
The invention relates to expressing proteins in the axons of mammalian neurons. The invention provides nucleic acids that can be used to express a selected polypeptide in neuronal axons, viruses that can be used deliver nucleic acids of the invention into neuronal axons, as well as methods for doing so. Thus, the invention provides pharmaceutical compositions comprising viruses of the invention, as well as their use in methods of treating injured axons or conditions associated with aberrant axon growth or function.